HIV proteins disrupt a network of phosphatidylinositol (4,5)‐bisphosphate binding sites on the dopamine transporter to regulate amphetamine behaviours
Amphetamine (AMPH) use has been linked to human immunodeficiency virus (HIV) transmission because HIV can spread through unprotected sex that is associated with AMPH use disorder (AUD). Thus, AUD and HIV have been termed a double epidemic. In this bidirectional relationship, the role played by AUD in HIV‐dependent neuropathogenesis is well documented. By contrast, how HIV infection regulates the development of AUD remains elusive. In rodents, expression of HIV viral proteins, such as the trans‐activator of transcription (Tat), enhances AMPH escalation (i.e. a progressive intensification of drug use), a Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) criteria for addiction. In humans, HIV infection increases AMPH frequency of use, as well as the total amount used. Thus, it is possible that HIV/HIV proteins promote the progression of AUD. AMPH‐associated behaviours stem, at least in part, from the ability of AMPH to reverse the dopamine (DA) transporter (DAT) function, causing non‐vesicular DA release (NVDR) and an increase in extracellular DA. Previously, we provided the first evidence that specific domains of DAT engage in direct association with the plasma membrane lipid, phosphatidylinositol 4,5‐bisphosphate (PIP 2 ). These interactions are essential for AMPH‐induced NVDR and specific behaviours. HIV Tat is a protein that binds PIP 2 through its basic domain. We demonstrate that Tat impairs NVDR by disrupting the network of PIP 2 binding sites on DAT. Our study provides an atomic scale mechanistic description on how Tat disrupts human DAT/PIP 2 association and blunts AMPH‐induced NVDR. Using Drosophila as an animal model, we show that Tat by blunting NVDR in the setting of AUD promotes AMPH escalation. image Key points Human immunodeficiency virus (HIV) trans‐activator of transcription (Tat) impairs non‐vesicular dopamine (DA) release (NVDR) by disrupting the network of PIP 2 binding sites on human Da transporter (DAT). Our study provides an atomic scale mechanistic description on how Tat disrupts human DAT/phosphatidylinositol 4,5‐bisphosphate association and blunts amphetamine (AMPH)‐induced NVDR. We associate Tat blunting of NVDR to the ability of Tat to foster AMPH escalation, using Drosophila as an animal model.
Authors
- Yanqi Zhu (ORCID: https://orcid.org/0000-0002-8631-0784)
- Mary Hongying Cheng (ORCID: https://orcid.org/0000-0001-5833-8221)
- Clarence Haddon Mullins (ORCID: https://orcid.org/0000-0002-3462-3690)
- Aurelio Galli (ORCID: https://orcid.org/0000-0001-7173-9345)
- Heinrich J. G. Matthies (ORCID: https://orcid.org/0000-0003-3615-7571)
- Angela M. Carter (ORCID: https://orcid.org/0000-0001-5766-3743)
- Daniele Zanella (ORCID: https://orcid.org/0000-0002-1821-6796)
- İvet Bahar (ORCID: https://orcid.org/0000-0001-9959-4176)
- Diksha Parwana (ORCID: https://orcid.org/0009-0002-0556-1803)
- Branden Duyvestyn
- Cesar E. Hernandez
- Hunter S Goffinet
- Siddhartha Nakkella
Institutions
- University of Alabama at Birmingham (US)
- UAB Medicine (US)
- Stony Brook University (US)
Publication Details
- Journal
- The Journal of Physiology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1113/jp291975
- Primary Topic
- Neurotransmitter Receptor Influence on Behavior
- Type
- article
- Field-Weighted Citation Impact
- 0.00